|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-12-28
|
|
pubmed:abstractText |
Availability of an ultra-short-course drug regimen capable of curing patients with tuberculosis in 2 to 3 mo would significantly improve global control efforts. Because immediate prospects for novel treatment-shortening drugs remain uncertain, we examined whether better use of existing drugs could shorten the duration of treatment. Rifapentine is a long-lived rifamycin derivative currently recommended only in once-weekly continuation-phase regimens. Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-11264046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-11316634,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-11432536,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-12045127,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-12241657,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-12588714,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-12678417,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-14578218,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-14962821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-15306535,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-15374844,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-15533952,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-15591164,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-15937767,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16141439,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16469488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16474028,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16513969,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16546546,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16574936,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16675781,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-16908866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-2155555,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-5314737,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-53598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-6356277,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-9620898,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18092886-9712273
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1549-1676
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
e344
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18092886-Animals,
pubmed-meshheading:18092886-Antibiotics, Antitubercular,
pubmed-meshheading:18092886-Antitubercular Agents,
pubmed-meshheading:18092886-Aza Compounds,
pubmed-meshheading:18092886-Colony Count, Microbial,
pubmed-meshheading:18092886-Disease Models, Animal,
pubmed-meshheading:18092886-Drug Administration Schedule,
pubmed-meshheading:18092886-Drug Therapy, Combination,
pubmed-meshheading:18092886-Isoniazid,
pubmed-meshheading:18092886-Lung,
pubmed-meshheading:18092886-Mice,
pubmed-meshheading:18092886-Mice, Inbred BALB C,
pubmed-meshheading:18092886-Mycobacterium tuberculosis,
pubmed-meshheading:18092886-Pyrazinamide,
pubmed-meshheading:18092886-Quinolines,
pubmed-meshheading:18092886-Recurrence,
pubmed-meshheading:18092886-Rifampin,
pubmed-meshheading:18092886-Time Factors,
pubmed-meshheading:18092886-Tuberculosis
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
|
|
pubmed:affiliation |
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, N.I.H., Extramural
|
